Putting Out the Fire in Acute Kawasaki Disease

In the report by Masuda and Kobayashi1 in this volume of The Journal, the outcomes are presented for 434 patients with acute Kawasaki disease who received infliximab at some point during their treatment course.1 The data were gathered retrospectively from 274 institutions across Japan and the diversity of approaches to the treatment of acute Kawasaki disease is readily apparent. Infliximab was administered as either the first-, second-, third-, or fourth-line agent in this cohort of patients, many of whom also received a variety of other treatments.

http://ift.tt/2FyM6hs